We are live on
!
Find out more
VIA
Virtus Investment Advisers Portfolio holdings
AUM
$363M
1-Year Est. Return
34.89%
This Fund
S&P 500
This Quarter
Est. Return
-1.68%
1 Year Est. Return
+34.89%
3 Year Est. Return
+131.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$368M
AUM Growth
+$240M
(+188%)
Cap. Flow
+$255M
Cap. Flow
% of AUM
69.4%
Top 10 Holdings %
Top 10 Hldgs %
25.49%
Holding
710
New
414
Increased
42
Reduced
13
Closed
237
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Virtus Newfleet ABS/MBS ETF
VABS
|
+$32.2M |
| 2 |
Virtus Newfleet Short Duration High Yield Bond ETF
VSHY
|
+$24.8M |
| 3 |
Virtus SEIX Senior Loan ETF
SEIX
|
+$19.2M |
| 4 |
SMC
Summit Midstream
SMC
|
+$4.35M |
| 5 |
OCCI
OFS Credit Co
OCCI
|
+$2.75M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ICICI Bank
IBN
|
+$3.75M |
| 2 |
Virtus Duff & Phelps Clean Energy ETF
VCLN
|
+$2.74M |
| 3 |
Apple
AAPL
|
+$2.06M |
| 4 |
Microsoft
MSFT
|
+$2.02M |
| 5 |
Primoris Services
PRIM
|
+$1.86M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 24.48% |
| 2 | Healthcare | 11.95% |
| 3 | Technology | 8.6% |
| 4 | Industrials | 8.02% |
| 5 | Energy | 4.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
401
Kura Oncology
KURA
$874M
| $112K | 0.03% |
+16,942
| New | +$132K |
|
|
TRML
402
DELISTED
Tourmaline Bio
TRML
| $111K | 0.03% |
+7,289
| New | +$117K |
|
403
Spyre Therapeutics
SYRE
$9.29B
| $111K | 0.03% |
+6,861
| New | +$143K |
|
404
Nuvation Bio
NUVB
$2.32B
| $110K | 0.03% |
+62,421
| New | +$142K |
|
405
Oric Pharmaceuticals
ORIC
$1.41B
| $109K | 0.03% |
+19,473
| New | +$170K |
|
406
Capricor Therapeutics
CAPR
$223M
| $109K | 0.03% |
+11,448
| New | +$159K |
|
407
Prime Medicine
PRME
$571M
| $109K | 0.03% |
+54,535
| New | +$139K |
|
408
Cartesian Therapeutics
RNAC
$265M
| $108K | 0.03% |
+8,160
| New | +$146K |
|
409
Kymera Therapeutics
KYMR
$9.03B
| $106K | 0.03% |
+3,891
| New | +$142K |
|
|
CMPS
410
Compass Pathways
CMPS
$1.78B
| $106K | 0.03% |
+37,225
| New | +$143K |
|
411
IDEAYA Biosciences
IDYA
$3.54B
| $104K | 0.03% |
+6,368
| New | +$136K |
|
412
Cullinan Oncology
CGEM
$1.18B
| $102K | 0.03% |
+13,455
| New | +$129K |
|
413
Immunovant
IMVT
$8.24B
| $102K | 0.03% |
+5,953
| New | +$125K |
|
414
Taysha Gene Therapies
TSHA
$1.83B
| $101K | 0.03% |
+72,957
| New | +$122K |
|
415
Perspective Therapeutics
CATX
$342M
| $101K | 0.03% |
+47,307
| New | +$142K |
|
416
Tyra Biosciences
TYRA
$1.57B
| $101K | 0.03% |
+10,818
| New | +$140K |
|
417
Immatics
IMTX
$1.33B
| $99.9K | 0.03% |
+22,153
| New | +$116K |
|
418
Arcturus Therapeutics
ARCT
$200M
| $99K | 0.03% |
+9,353
| New | +$148K |
|
419
Crinetics Pharmaceuticals
CRNX
$8.93B
| $99K | 0.03% |
+2,953
| New | +$110K |
|
|
MREO
420
Mereo BioPharma
MREO
$43.5M
| $99K | 0.03% |
+44,007
| New | +$124K |
|
421
Biohaven
BHVN
$2.19B
| $98.2K | 0.03% |
+4,083
| New | +$144K |
|
422
Monte Rosa Therapeutics
GLUE
$1.35B
| $97.8K | 0.03% |
+21,073
| New | +$129K |
|
423
Wave Life Sciences
WVE
$1.2B
| $95.7K | 0.03% |
+11,850
| New | +$130K |
|
424
Altimmune
ALT
$593M
| $95.6K | 0.03% |
+19,116
| New | +$121K |
|
425
Denali Therapeutics
DNLI
$4B
| $95K | 0.03% |
+6,991
| New | +$134K |
|
Similar funds
WI
MS
HS
SIAG
WTFG
A6
ACM
RGC
Virtus Investment Advisers's Q1 2025 Portfolio in Review
As of Q1 2025, Virtus Investment Advisers held 710 positions worth $368M, up 188% from $128M the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Virtus Investment Advisers deployed $255M of net new capital in Q1 2025, opening 414 new positions and adding to 42 existing holdings. Its largest new stake was Virtus Newfleet ABS/MBS ETF: 1,321,000 shares worth $32.2M.
By sector, the portfolio is most concentrated in Financials at 24% of assets, up from 16% a quarter earlier, followed by Healthcare and Technology.
On the sell side, the largest reduction was Berry Corp, an estimated $666K trimmed.
- Virtus Investment Advisers's largest Q1 2025 buy was Virtus Newfleet ABS/MBS ETF: 1,321,000 shares worth $32.2M.
- Virtus Investment Advisers added most to Yum China in Q1 2025, an estimated $1.42M increase.
- Virtus Investment Advisers's biggest Q1 2025 reduction was Berry Corp, cutting an estimated $666K.
- Virtus Investment Advisers fully exited ICICI Bank in Q1 2025, selling an estimated $3.75M.
- Virtus Investment Advisers's ten largest holdings make up 25% of its $368M portfolio in Q1 2025.
- Virtus Investment Advisers opened 414 new positions and closed 237 in Q1 2025.
- Virtus Investment Advisers's portfolio value rose 188% quarter-over-quarter to $368M.
Based on Virtus Investment Advisers's 13F filing for Q1 2025, filed 15 May 2025.